SCHEMBL5541402

SCHEMBL5541402

O=[C]OCc1ncc(-c2ccccc2)s1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.54
FEN1 P39748 1/20 0.54
LOXL2 Q9Y4K0 3/20 0.50
LOXL3 P58215 1/20 0.41
KDR P35968 8/20 0.41
HTR7 P34969 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CDK5 Q00535 1/20 0.40
ACP1 P24666 1/20 0.38
GSTO1 P78417 1/20 0.38
HSD17B13 Q7Z5P4 1/20 0.37
SCD O00767 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543359 0.80 FEN1 (0.34) ERCC5FEN1LOXL2
SCHEMBL5536697 0.76 ALDH1A1 (0.41) FEN1CYP3A4
SCHEMBL9665362 0.73 LOXL2 (0.58) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL28207097 0.73 LOXL2 (0.58) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL17014778 0.73 LOXL2 (0.58) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL2226631 0.73 LOXL2 (0.58) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL2226003 0.73 ERCC5 (0.63) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL8830055 0.73 LOXL2 (0.58) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL21812622 0.73 LOXL2 (0.84) ERCC5FEN1LOXL2LOXL3KDR
SCHEMBL31595961 0.72 ERCC5 (0.58) ERCC5FEN1LOXL2LOXL3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ERCC5 4470/4885FEN1 3996/4885LOXL2 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.